Philip A. Van Den Reek

Nijmegen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Bridging theory and practice in model-informed precision dosing of medication in inflammatory skin diseases.

Bridging theory and practice in model-informed precision dosing of medication in inflammatory skin diseases.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: January 02, 2026

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study.

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: September 05, 2025

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 30, 2025

Exploring the Disease Duration of Urticaria and Associated Determinants in Primary Care.

Exploring the Disease Duration of Urticaria and Associated Determinants in Primary Care.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: June 19, 2025

Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review.

Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review.

Journal: Frontiers in pharmacology
Published: October 03, 2024

Psoriasis healthcare during the COVID-19 pandemic: a survey among psoriasis patients (PsoCovidCare).

Psoriasis healthcare during the COVID-19 pandemic: a survey among psoriasis patients (PsoCovidCare).

Journal: The Journal of dermatological treatment
Published: June 19, 2024

Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study.

Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study.

Journal: Allergy
Published: May 17, 2024

Dose reduction of biologics in patients with plaque psoriasis: a review.

Dose reduction of biologics in patients with plaque psoriasis: a review.

Journal: Frontiers in pharmacology
Published: January 13, 2024

Multi-treatment resistance to biological treatment in patients with psoriasis: Definitions and implications.

Multi-treatment resistance to biological treatment in patients with psoriasis: Definitions and implications.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: January 04, 2024

The lifestyle of psoriasis patients and their motivation to change.

The lifestyle of psoriasis patients and their motivation to change.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: November 09, 2023

Exclusion by age, cardiovascular comorbidity and malignancies are the main factors that impact generalizability of evidence from trials to the real-world situation in older adults with psoriasis.

Exclusion by age, cardiovascular comorbidity and malignancies are the main factors that impact generalizability of evidence from trials to the real-world situation in older adults with psoriasis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 06, 2023

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice.

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice.

Journal: The Journal of dermatological treatment
Published: March 03, 2023
Showing 1-12 of 27

Last Updated: 09/26/2026